ANNEX III Labelling of outer/immediate packaging referred to in Article 11, Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 Novembe…

In force
(a)

The name of the medicinal product and, if appropriate, an indication of whether it is intended for babies, children or adults; the international non-proprietary name (INN) shall be included, or, if the product has no INN, the common name;

(b)

A description of the active substance(s) expressed qualitatively and quantitatively, including, where the product contains cells or tissues, the statement ‘This product contains cells of human/animal [as appropriate{] origin’ together with a short description of these cells or tissues and of their specific origin, including the species of animal in cases of non-human origin;

(c)

The pharmaceutical form and, if applicable, the contents by weight, by volume or by number of doses of the product;

(d)

A list of excipients, including preservative systems;

(e)

The method of use, application, administration or implantation and, if necessary, the route of administration. If applicable, space shall be provided for the prescribed dose to be indicated;

(f)

A special warning that the medicinal product must be stored out of the reach and sight of children;

(g)

Any special warning necessary for the particular medicinal product;

(h)

The expiry date in clear terms (month and year; and day if applicable);

(i)

Special storage precautions, if any;

(j)

Specific precautions relating to the disposal of unused medicinal products or waste derived from medicinal products, where appropriate, as well as reference to any appropriate collection system in place;

(k)

The name and address of the marketing authorisation holder and, where applicable, the name of the representative appointed by the holder to represent him;

(l)

Marketing authorisation number(s);

(m)

The manufacturer’s batch number and the unique donation and product codes referred to in Article 8(2) of Directive 2004/23/EC;

(n)

In the case of advanced therapy medicinal products for autologous use, the unique patient identifier and the statement ‘For autologous use only’.